CARMN Loss Regulates Smooth Muscle Cells and Accelerates Atherosclerosis in Mice
Francesca Vacante,Julie Rodor,Mukesh K. Lalwani,Amira D. Mahmoud,Matthew Bennett,Azzurra L. De Pace,Eileen Miller,Kim Van Kuijk,Jenny de Bruijn,Marion Gijbels,Thomas C. Williams,Michael B. Clark,Jessica P. Scanlon,Amanda C. Doran,Rusty Montgomery,David E. Newby,Mauro Giacca,Dónal O’Carroll,Patrick W.F. Hadoke,Laura Denby,Judith C. Sluimer,Andrew H. Baker,Mukesh K Lalwani,Amira D Mahmoud,Azzura De Pace,Kim van Kuijk,Jenny BG de Bruijn,Thomas Christie Williams,Michael B Clark,Jessica P Scanlon,Amanda C Doran,David E Newby,Dónal O'Carroll,Patrick WF Hadoke,Judith C Sluimer,Andrew H Baker
DOI: https://doi.org/10.1161/CIRCRESAHA.120.318688
IF: 23.213
2021-02-26
Circulation Research
Abstract:Rationale: In the microenvironment of atherosclerotic lesions, vascular smooth muscle cells (vSMCs) switch to a dedifferentiated state but the underlying molecular mechanisms driving this switch are not fully understood. Long noncoding RNAs (lncRNAs) are dysregulated during vascular pathology, but relatively little is known about their involvement in controlling vSMCs function. CARMN is a lncRNA located immediately upstream of the microRNAs (miRNAs) miR-143 and miR-145, both involved in vSMCs function. Objective: We investigated the role of the lncRNA CARMN, independent from miR-143 and miR-145, as potential a regulator of vSMC phenotypes in vitro and the consequences of its loss during the development of atherosclerosis in vivo. We hypothesized that loss of CARMN is a primary event controlling the functional switch towards pro-atherogenic vSMC phenotype and accelerates the development of the plaques in vivo. Methods and Results: Expression of CARMN lncRNA was silenced using GapmeRs in human coronary arterial smooth muscle cells (hCASMCs), revealing that GapmeR-mediated loss of CARMN negatively affects miR-143 and miR-145 miRNA expression. RNA sequencing of CARMN-depleted hCASMCs revealed large transcriptomic changes, associated with vSMC proliferation, migration, inflammation, lipid metabolism and dedifferentiation. The use of miR-143 and miR-145 mimics revealed that CARMN regulates hCASMC proliferation in a miRNA-independent manner. In human and mouse, CARMN and associated miRNAs were downregulated in advanced versus early atherosclerotic lesions. Using a CRISPR-Cas9 knock-out approach, we explored the implications of CARMN depletion during atherosclerosis in vivo. Consistent with in vitro results, the knock-out of CARMN impaired the expression of miR-143 and miR-145 under homeostatic conditions. Importantly, when atherosclerosis was induced in these mice, CARMN knock-out increased the volume, size, pro-inflammatory LGALS3-expressing cells content and altered plaque composition, yielding an advanced phenotype. Conclusions: We identified the early loss of CARMN lncRNA as critical event which primes vSMCs towards a pro-atherogenic phenotype in vitro and accelerates the development of atherosclerosis in vivo.
cardiac & cardiovascular systems,peripheral vascular disease,hematology